Biogen Details $5.6B Apellis Deal, Sees Mid-to-High-Teens Growth and EPS Accretion by 2027.
Share this article
Analysis
Neutral
Biogen Details $5.6B Apellis Deal, Sees Mid-to-High-Teens Growth and EPS Accretion by 2027
Mar 31, 2026 14:10 UTC
Stay Ahead of the Markets
Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.